Dizal (Jiangsu) Pharmaceutical (SHA:688192) presented the results of its phase 1/2 drug trial of its lung cancer treatment in a journal of the European Society for Medical Oncology, according to a filing with the Shanghai Stock Exchange.
The drug is the only standard treatment for second or later-line non-small cell lung cancer with epidermal growth factor exon 20 insertion mutations, according to the filing.
During the trial the drug showed "good" anti-tumor activity and safety in patients, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.